GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation

Neuropathic Pain Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01291316
• Other study ID #: GABA-SPUM
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: February 7, 2011
• Last updated: December 13, 2011
• Start date: April 2010
• Est. completion date: November 2011

Study information

• Verified date: December 2011
• Source: University Hospital, Geneva
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

In animal, the GABAergic system modulates central sensitisation, which is a key phenomenon in pain processing. The development of GABAA agonists targeting the subunits of the GABAA receptor implicated in nociception, but not the subunit implicated in sedation is attractive as it opens new perspectives of testing the role of GABAergic modulation of pain processing in human volunteers. The purpose of this subproject is to test the effect of the specific α2 and α3 agonist but sparing α1 effect TPA023 on a human model of peripheral and central sensitisation and to correlate its pharmacodynamic effect with the pharmacokinetic of the compound.

The results would contribute to clarify the potential role of these α2/α3 agonist but sparing α1drugs in clinical pain conditions.

Description:

Objectives:

• To assess the effect of the GABAA agonist clobazam on central sensitisation (change in the size of the area of secondary hyperalgesia) in healthy volunteers.

• To assess the effect of the GABAA agonist clobazam on peripheral sensitisation.

• To assess the effect of the GABAA agonist clobazam on sedation.

• To correlate the pharmacokinetic of clobazam to its effect (PK-PD modelling)

• To describe the role of the polymorphisms of CYP450 2C19 in the pharmacokinetic and dynamic of clobazam.

Methodology :

phase II , exploratory, three arms randomised placebo-controlled, double blind cross-over study in healthy volunteers

Number of patients : 25

Test product,Dose, Route of administration :

Clobazam,20 mg,oral intake

Duration of treatment :

Single dose administration of each compound

Reference therapy :

Clonazepam 1mg, oral intake Tolterodine 1, 37mg, oral intake

Other therapy :

Flumazenil 0.2mg, intravenous

Efficacy evaluation :

1. Determination of the impact of clobazam:

• on the size of the area of secondary hyperalgesia induced by an UVB irradiation of the skin (sunburn model). The area is mapped with an electronical Von Frey filament

• on the pain threshold (heat, static and mechanical threshold) in the primary and secondary area of hyperalgesia

• on the nociceptive flexion reflex

• on tolerance pain threshold (cold pressor test)

• on the degree of sedation measured by saccadic eye movements, digit substation symbols test (DSST) and numerical rating scale.

2. Determination of the concentration-time curve of clobazam and PK-PD modelling.

Statistical Methods :

Based on the results of a previous study done in our unit, assessing the effect of the association of paracetamol and ketorolac on the sunburn model30, the number of volunteers required to detect a 30% reduction in the area of hyperalgesia is 4830. However we chose a lower intensity of UVB irradiation than in previous studies. Using a dose of irradiation of 3 med , this number falls to 18, adopting a 5% level for statistical significance and a 80% power. Taking these two results in account we will go for 25 volunteers.

Data will be analysed by multifactorial analysis of variance (MANOVA) and by analysis of variance (ANOVA) with repeated measures In the case of withdrawal, the data obtained will not be used in the analysis. Data set will however be completed by enrolling a substitute volunteer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: November 2011
• Est. primary completion date: November 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Male subject, age between 18 and 60 year old

• Caucasian

• Type 3 skin phototype

• Non smoker or moderate smoker (< 10 cigarettes/day)

• No clinically abnormal findings on history and/or on physical examination

• Presence of an area of secondary hyperalgesia after UVB irradiation

Exclusion Criteria:

• Any concomitant illness

• Current or past history of drug and alcohol abuse or current intake of more than 3 glasses of alcohol a day or more than 21 glasses of alcohol per week

• Psychotropic drug intake during the last month

• Sun allergy or any skin disease

• Current and regular intake of any drugs that might affect nociception Paracetamol, or NSAIDS with a short half lives are permitted but should be stopped at least 48 h before the UVB session

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Neuralgia
• Neuropathic Pain

Intervention

Drug:
• Clonazepam
clonazepam, 1 mg, single oral dose
• Tolterodine
Tolterodine 1,37mg, single oral dose
• clobazam
clobazam 20 mg, single oral dose

Locations

Country	Name	City	State
Switzerland	University Hospitals	Geneva

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Geneva

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of the impact of clobazam on the change in the area of secondary hyperalgesia (in cm2) mapped with a Von Frey filament (256mN).		3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Change in the pain threshold (heat (°C) static mechanical (g) and dynamic mechanical (Numerical rating scale NAS) in the area of secondary hyperalgesia		3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Change in the pain threshold (heat (°C ) static mechanical (g) and dynamic mechanical (NAS)) in the area of primary hyperalgesia		3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Change in Nociceptive Flexion Reflex		3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Change in the latency and in the area under the pain intensity/time curve in cold pressor test		3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Change in mean target saccades peak velocity, target saccades acceleration and deceleration, in saccade latency (msec), in saccadic accuracy, in smooth pursuit lead time and in the number of saccadic intrusions in the smooth pursuit.		3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Change in the total number and in the correct number of symbols drawn in the DDST challenge.		3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Time concentration curve evaluation: blood samples at 0,5, 1, 2, 4, 6, 8,12, and at 24 hours post-dose	Clobazam and N-desmethylclobazam concentrations (µg/mL)	3 single days spaced out with at least two weeks wash-out periods	No
Secondary	Pharmacokinetic/ pharmacodynamic modelling.		3 single days spaced out with at least two weeks wash-out periods	No